Delving into the Latest Updates on JT-15 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Colonic CancerLung CancerOvarian Cancer

Inactive Indication-

Originator Organization

Canget BioTekpharma LLC

Active Organization

Canget BioTekpharma LLC

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

Viral infection generally induces polyclonal neutralizing antibody responses. However, how many lineages of antibody responses can fully represent the neutralization activities in sera has not been well studied. Using the newly designed stable HIV-1 Env trimer as hook, we isolated two distinct broadly neutralizing antibodies (bnAbs) from Chinese rhesus macaques infected with SHIV1157ipd3N4 for 5 years. One lineage of neutralizing antibodies (JT15 and JT16) targeted the V2-apex in the Env trimers, similar to the J038 lineage bnAbs identified in our previous study. The other lineage neutralizing antibody (JT18) targeted the V3 crown region in the Env, which strongly competed with human 447-52D. Each lineage antibody neutralized a different set of viruses. Interestingly, when the two neutralizing antibodies from different lineages isolated from the same macaque were combined, the mixture had a neutralization breath very similar to that from the cognate sera. Our study demonstrated that a minimum of two different neutralizing antibodies can fully recapitulate the serum neutralization breadth. This observation can have important implications in AIDS vaccine design.

100 Deals associated with JT-15

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colonic Cancer	Discovery	US	Canget BioTekpharma LLC	17 Mar 2022
Lung Cancer	Discovery	US	Canget BioTekpharma LLC	17 Mar 2022
Ovarian Cancer	Discovery	US	Canget BioTekpharma LLC	17 Mar 2022